Biogen, a leading US biotechnology firm, has reached a significant agreement to acquire Pfizer’s neurology drug candidate, PF-04958242, which is being developed to address cognitive impairment associated with schizophrenia (CIAS). The deal, potentially worth almost $600 million, includes an upfront payment of $75 million, with additional milestone payments and royalties that could total up to […]
Significant Acquisition in Pharma Industry: US pharmaceutical giant Merck has announced a definitive agreement to acquire Viralytics, an Australian biotech company, for AUD 502 million (approximately $394 million). This acquisition is set to significantly enhance Merck’s portfolio in the burgeoning field of immuno-oncology. Strategic Expansion of Immuno-Oncology Pipeline: Through this acquisition, Merck aims to expand […]
Roche, the Swiss pharmaceutical giant, has announced its plans to fully acquire Flatiron Health, a leading oncology software company, for $1.9 billion. This strategic move aims to fast-track the development of cancer treatments by leveraging Flatiron Health’s advanced data analytics and electronic health records software. Strategic Expansion in Oncology The acquisition marks a significant step […]
Seattle Genetics, a leader in oncology biotechnology, has announced the acquisition of Cascadian Therapeutics for approximately $614 million, a strategic move to enhance its portfolio of solid tumor treatments. The acquisition, which involves Seattle Genetics paying $10 per share in cash for the California-based company, is set to significantly advance its research in cancer therapies, […]
French pharmaceutical giant Sanofi has successfully finalized an agreement to acquire Ablynx, a Belgian biotechnology firm, for approximately €3.9 billion. This strategic acquisition surpasses a previous offer of €2.6 billion from Danish pharmaceutical company Novo Nordisk, which Ablynx had rejected citing undervaluation. Details of the Acquisition Ablynx, based in Ghent and established in 2001 as […]
Sanofi has announced a definitive agreement to acquire Bioverativ, a US biotechnology company specializing in the treatment of hemophilia and other rare blood disorders, for approximately $11.6 billion. The all-cash transaction will involve Sanofi purchasing all outstanding shares of Bioverativ at $105 per share, marking a significant expansion of Sanofi’s presence in specialty care and […]
Japanese pharmaceutical giant Takeda Pharmaceutical has announced a proposal to acquire TiGenix, a Belgium-based cell therapy company, for €520 million. This acquisition is aimed at expanding Takeda’s late-stage gastroenterology portfolio and enhancing its presence in the American specialty care market. TiGenix, established in 2000, specializes in the development of novel treatments for serious medical conditions […]
In a strategic move to broaden its pharmaceutical offerings, UK-based Mallinckrodt has announced the acquisition of Sucampo Pharmaceuticals, including its commercial and developmental assets, for approximately $1.2 billion. This acquisition also involves the assumption of $360 million of Sucampo’s debt, signaling a significant investment by Mallinckrodt into expanding its specialty pharmaceutical and rare disease sectors. […]
Roche Pharmaceuticals, a prominent Swiss pharmaceutical company, has entered into a definitive merger agreement to acquire Ignyta, a U.S. cancer drug maker, for $1.7 billion in an all-cash transaction. This acquisition, priced at $27 per share, significantly bolsters Roche’s oncology portfolio by adding advanced gene therapy-based cancer drugs that are in the early stages of […]
Teva Pharmaceutical Industries, the Israel-based generic drug manufacturer, has unveiled a drastic two-year restructuring plan aimed at rejuvenating its business and enhancing financial performance. The plan includes the elimination of 14,000 positions, representing over a quarter of its global workforce. This move is part of a broader strategy to reduce the company’s overall cost base […]